A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).

Trial Profile

A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs CP 866087 (Primary)
  • Indications Female sexual dysfunction
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Nov 2008 Actual end date changed from 1 Nov 2008 to 1 Oct 2008 as reported by Clinicaltrials.gov.
    • 03 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2008 New locations added according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top